Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Consensus Recommendation of “Moderate Buy” by Analysts

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) has been assigned an average recommendation of “Moderate Buy” from the six research firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $8.00.

A number of analysts have recently weighed in on MIST shares. TD Cowen upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, December 15th. HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Milestone Pharmaceuticals in a research report on Tuesday, January 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research note on Monday, December 29th. Zacks Research raised shares of Milestone Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 26th. Finally, Wells Fargo & Company lifted their price objective on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th.

Milestone Pharmaceuticals Stock Performance

NASDAQ MIST opened at $1.76 on Friday. Milestone Pharmaceuticals has a 52-week low of $0.63 and a 52-week high of $3.06. The company has a fifty day moving average of $2.15 and a 200-day moving average of $1.98. The company has a market capitalization of $149.90 million, a P/E ratio of -2.15 and a beta of 0.46. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.05. As a group, equities research analysts predict that Milestone Pharmaceuticals will post -0.62 EPS for the current fiscal year.

Insider Transactions at Milestone Pharmaceuticals

In other news, CEO Joseph Oliveto sold 34,523 shares of the business’s stock in a transaction on Monday, January 26th. The shares were sold at an average price of $1.93, for a total transaction of $66,629.39. Following the sale, the chief executive officer owned 482,744 shares in the company, valued at approximately $931,695.92. The trade was a 6.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Jeffrey Edward Nelson sold 58,007 shares of the stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $2.32, for a total transaction of $134,576.24. Following the completion of the transaction, the chief operating officer owned 41,993 shares of the company’s stock, valued at approximately $97,423.76. The trade was a 58.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 416,327 shares of company stock valued at $935,458 in the last three months. Company insiders own 19.50% of the company’s stock.

Hedge Funds Weigh In On Milestone Pharmaceuticals

Several large investors have recently made changes to their positions in MIST. Strategic Family Wealth Counselors L.L.C. bought a new stake in shares of Milestone Pharmaceuticals in the 4th quarter worth approximately $25,000. October Effect Ltd purchased a new stake in shares of Milestone Pharmaceuticals in the fourth quarter worth $105,000. SG Americas Securities LLC bought a new position in shares of Milestone Pharmaceuticals during the fourth quarter valued at $197,000. Bay Rivers Group raised its position in shares of Milestone Pharmaceuticals by 72.9% in the 4th quarter. Bay Rivers Group now owns 28,861 shares of the company’s stock worth $58,000 after purchasing an additional 12,170 shares during the last quarter. Finally, Millennium Management LLC purchased a new position in shares of Milestone Pharmaceuticals in the 3rd quarter worth about $803,000. 86.18% of the stock is currently owned by hedge funds and other institutional investors.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.